4 terminated, 3 completed. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Terminated 4, Completed 3 |
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq) - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Terminated | Macquarie University, Australia | 12 | 2024-11-15 | 2025-06-08 |
| Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS MT-1186 - ALS | Phase 3 | Completed | Shionogi | 15 | 2022-10-26 | 2026-07-21 |
| Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS MT-1186, Placebo - ALS | Phase 3 | Terminated | Shionogi | 202 | 2022-01-11 | 2026-10-21 |
| Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS MT-1186, Placebo - ALS | Phase 3 | Terminated | Shionogi | 384 | 2020-11-13 | 2026-07-20 |
| An Efficacy and Safety Study of Ravulizumab in ALS Participants Placebo, Ravulizumab - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 382 | 2020-03-30 | 2023-01-10 |
| Safety Study of Oral Edaravone Administered in Subjects With ALS MT-1186 - ALS | Phase 3 | Completed | Shionogi | 185 | 2019-11-18 | 2026-07-21 |
| Clinical Trial Ceftriaxone in Subjects With ALS ceftriaxone, placebo - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Completed | Massachusetts General Hospital | 513 | 2006-07-01 | 2014-04-21 |
Amyotrophic Lateral Sclerosis (3) · Motor Neuron Disease (1)
Central Nervous System Diseases (3) · Metabolic Diseases (3) · Nervous System Diseases (3) · Neurodegenerative Diseases (3) · Neuromuscular Diseases (3) · Nutritional and Metabolic Diseases (3) · Proteostasis Deficiencies (3) · Spinal Cord Diseases (3) · TDP-43 Proteinopathies (3) · Motor Neuron Disease (2)
Edaravone (4) · Ceftriaxone (1) · Lamivudine (1) · abacavir (1) · abacavir, dolutegravir, and lamivudine drug combination (1) · dolutegravir (1) · ravulizumab (1)
Shionogi (4) · Alexion Pharmaceuticals, Inc. (1) · Macquarie University, Australia (1) · Massachusetts General Hospital (1)
Canada (5) · Japan (5) · United States (5) · Germany (4) · Italy (3) · Switzerland (3) · Australia (2) · France (2) · South Korea (2) · Belgium (1) · Denmark (1) · Ireland (1) · Israel (1) · Netherlands (1) · Poland (1)
PMID 23613806, PMID 25297012, PMID 28864675, PMID 36504406, PMID 37695623, PMID 40474686
2019 (2), U01NS049640 (1)